GW Pharmaceuticals selects infantile spasms for Epidiolex development program
The company secured orphan drug designation from the US Food and Drug Administration for Epidiolex (cannabidiol or CBD) to treat IS. A two-part pivotal Phase 3 study is
VERTANICAL has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for VER-01, its investigational non-opioid treatment for chronic low back pain.
Under the double-blind, double-dummy, parallel group FULFIL study, 1,810 patients were randomized to receive either GSK’s fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or budesonide/formoterol. The study met its objectives, with the
Adaptimmune previously received orphan drug destination from the U.S. Food and Drug Administration for its NY-ESO SPEAR T-cell therapy in this indication. "While unresectable or metastatic soft tissue